PMV Pharma Q1 loss narrows to $15.3M; Phase 2 PYNNACLE trial initiated

PMV Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.30

Net loss $15.3M vs $19.1M YoY; cash $213.1M, expected runway to end of 2026.
First patient dosed in registrational Phase 2 PYNNACLE trial for rezatapopt (TP53 Y220C/KRAS wild-type).
Phase 1 ovarian cancer data: 7/15 confirmed partial responses, median duration 7 months.
R&D expenses $13.2M (down from $15.1M); G&A $5.0M (down from $6.4M).
Net cash used in operations $16.2M vs $15.0M in Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $15.3 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss for the quarter ended March 31, 2024, was $15.3 million
Result: reported results

Exact text from the filing

PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.